CDKN2A and adenocarcinoma: The frequency of CDKN2A alterations in pancreatic (47.8%) and biliary tract (31.1%) adenocarcinomas was significantly higher than that in stomach (17.5%) and colorectal (1.4%) adenocarcinomas (p < 0.01) (Table S4).